Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.

@article{Wroblewski2009PegaptanibSF,
  title={Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.},
  author={John J Wroblewski and John A Wells and Anthony P. Adamis and Ronald R Buggage and Emmett T. Cunningham and Mauro Goldbaum and David R. Guyer and Barrett Katz and Michael M. Altaweel},
  journal={Archives of ophthalmology},
  year={2009},
  volume={127 4},
  pages={374-80}
}
OBJECTIVES To assess the safety and efficacy of intravitreous pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO). DESIGN This dose-ranging, double-masked, multicenter, phase 2 trial included subjects with CRVO for 6 months' or less duration randomly assigned (1:1:1) to receive pegaptanib sodium or sham injections every 6 weeks for 24 weeks (0.3 mg and 1 mg, n=33; sham, n=32). MAIN OUTCOME MEASURE Visual acuity at week 30. RESULTS In the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…